A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
← catalyst calendarNCT06476808 · readout in 853 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
240estimated
Sites
17
Countries
Canada, France, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-06 | actual | When the study began enrolling |
| Primary completion | 2028-12-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-19 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- High-grade Serous Ovarian Carcinoma (HGSOC)
- Uterine Serous Carcinoma (USC)
- Non-small Cell Lung Cancer (NSCLC)
Intervention
- Drug: BMS-986463
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 108 weeks
Number of participants with serious adverse events (SAEs)
measured Up to 108 weeks
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
measured Up to 108 weeks
Number of participants with AEs leading to discontinuation
measured Up to 108 weeks
Number of participants with AEs leading to death
measured Up to 108 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed